NEW YORK, November 8, 2016 /PRNewswire/ --
Stock-Callers.com brings focus back on the Drug Manufacturers industrywhich consists of companies that research, develop, market, and distribute drugs for nearly every therapeutic need. Four major players have been lined up for assessment this morning: Eli Lilly and Co. (NYSE: LLY), Provectus Biopharmaceuticals Inc. (OTCMKTS:
At the close on Monday, shares in Indianapolis, Indiana headquartered Eli Lilly and Co. rose 1.92%, ending the day at $73.88. The stock recorded a trading volume of 4.96 million shares, which was above its three months average volume of 3.65 million shares. The Company's shares are trading below their 200-day moving average by 3.12%. Moreover, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 35.15.
On November 03rd, 2016, Eli Lilly announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase 3 studies, along with findings from a real-world assessment of medication use among rheumatoid arthritis patients and other phase 2 studies, will be presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Washington DC, November 11th -16th, 2016. Additionally, six abstracts, including one oral presentation, will feature results from pivotal phase 3 data of Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. Visit us today and download your complete report on LLY for free at:
Shares in Knoxville, Tennessee-based Provectus Biopharmaceuticals Inc. ended the day 6.90% lower at $0.05 and with a total trading volume of 964,091 shares. The stock is trading below its 50-day moving average by 37.78%. Shares of the Company, which engages in developing ethical pharmaceuticals for oncology and dermatology indications, have an RSI of 40.48.
On October 25th, 2016, Provectus Biopharma announced that it will host its Q3 2016 business update conference call on November 14th, 2016 at 4 p.m. ET. Management will provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors. The complimentary research report on PVCT can be accessed at:
On Monday, shares in Brentford, the UK headquartered GlaxoSmithKline PLC finished 0.54% higher at $38.84. A total volume of 3.32 million shares was traded, which was above their three months average volume of 2.91 million shares. The stock has advanced 2.97% on an YTD basis. The Company's shares are trading below their 200-day moving average by 5.21%. Additionally, shares of GlaxoSmithKline, which creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 29.52.
On October 26th, 2016, GlaxoSmithKline reported that Group turnover for Q3 2016 increased 23% in Sterling terms to £7,542 million, with Pharmaceuticals up 6%, Vaccines up 20%, and Consumer Healthcare up 5%. Sales of New Pharmaceutical and Vaccine products were £1,212 million in the quarter, an increase of 79%. For Q3 2016, core operating profit was £5,709 million, 14% higher in CER terms than Q3 2015. The core operating margin of 28.1% was 3.3% higher than Q3 2015.
On October 20th, 2016, research firm Investec initiated a 'Buy' rating on the Company's stock. Register for free on Stock-Callers.com and download the PDF research report on GSK at:
Basel, Switzerland headquartered Novartis AG's shares recorded a trading volume of 2.77 million shares, which was higher than their three months average volume of 2.01 million shares. The stock closed the day at $70.90, gaining 0.93%. The Company's shares are trading below their 200-day moving average by 8.10%. Additionally, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI at 31.31.
On October 10th, 2016, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $92 a share.
On October 25th, 2016, Novartis reported that net sales were $12.1 billion in Q3 2016, as volume growth of 5% was more than offset by the negative impact of generic competition and pricing. Core operating income was $3.4 billion. Core operating income margin in constant currencies decreased 0.6%, mainly due to investments behind new launches and the Alcon growth plan, partially offset by productivity improvements. Novartis' net income was $1.9 billion. Get free access to your research report on NVS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All